Interactions of 4-Quinolones with Other Agents — The Importance in Assessing Practical Antibacterial Potency

  • C. S. Lewin
  • J. T. Smith
Part of the Springer Series in Applied Biology book series (SSAPPL.BIOLOGY)


The 4-quinolones are broad spectrum antibacterials and therefore are generally used as single antimicrobial agents. However, in certain situations, they can be combined with a second antibacterial to provide better anti-staphylococcal and anti-streptococcal activity. For example, when empirically treating febrile episodes in immunocompromised patients (Smith et al. 1988). Furthermore, it has been suggested that the 4-quinolones should be used in conjunction with a second antibacterial in order to prevent the emergence of 4-quinolone-resistant organisms during therapy (Scully et al. 1986; Farrag et al. 1986).


Minimum Inhibitory Concentration Nutrient Broth Nalidixic Acid Antimicrob Agent Neutropenic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bustamente CI, Drusano GL, Wharton RC, Wade JC (1987) Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 31:632–634Google Scholar
  2. Chalkley U, Koornhof HJ (1985) Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother 28:331–342PubMedGoogle Scholar
  3. Chao L (1978) An unusual interaction between the target of nalidixic acid and novobiocin. Nature 271:385–386PubMedCrossRefGoogle Scholar
  4. Cullen ME, Wyke AW, McEachem F, Austin CA, Fisher LM (1989) Inhibition of DNA gyrase: Bacterial sensitivity and clinical resistance to 4-quinolones. Current Topics in Infectious Diseases and Clinical Microbiology 2:41–47Google Scholar
  5. Davies GSR, Cohen J (1985) In vitro study of the activity of ciprofloxacin against strains of Pseudomonas aeruginosa with multiple antibiotic resistance. J Antimicrob Chemother 16:713–717PubMedCrossRefGoogle Scholar
  6. Davis BD, Chen L, Tai PC (1986) Misread protein creates membrane channels: an essential step in the bactericidal action of the aminoglycosides. Procs Nat Acad Sci 83:6164–6168CrossRefGoogle Scholar
  7. Davis BD (1987) Mechanism of bactericidal action of aminoglycosides. Microbiol Revs 51:341–350Google Scholar
  8. Dietz WH, Cook TM, Goss WA (1966) Mechanism of action of nalidixic acid on Escherichia coli. IQ conditions required for lethality. J Bacteriol 94:768–773Google Scholar
  9. Drlica K, Franco RJ (1988) Inhibitors of DNA topoisomerases. Biochemistry 27:2254–2259CrossRefGoogle Scholar
  10. Dworkin RJ, Lee BL, Sande MA, Chambers HF (1989) Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. The Lancet ii:1071–1073CrossRefGoogle Scholar
  11. Farrag NN, Bendig JWA, Talboys C, Azadian BS (1986) In vitro study of the activity of ciprofloxacin combined with amikacin or ceftazidine against Pseudomonas aeruginosa. J Antimicrob Chemother 18:770CrossRefGoogle Scholar
  12. Fu KP, Hetzel N, Gregory J, Hung PP (1987) Therapeutic efficacy of cefpirimide ciprofloxacin combination in experimental Pseudomonas infections in neutropenic mice. J Antimicrob Chemother 20:541–546PubMedCrossRefGoogle Scholar
  13. Giamerellou H, Petrikos G (1987) Ciprofloxacin interaction with imipenem and amikacin against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 31:959–961Google Scholar
  14. Hackbarth CJ, Chambers HF, Sande MA (1986) Serum bactericidal activity of rifampin in combinations with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 29:611–613PubMedGoogle Scholar
  15. Haller I (1985) Comprehensive evaluation of ciprofloxacin-aminoglycoside combination against enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 28:663–666PubMedGoogle Scholar
  16. Henry NK, Rouse MS, Whitesell AL, McConnell ME, Wilson WR (1987) Treatment of methicillin-resistant Staphylococcus aureus experimental osteomylitis with ciprofloxacin and vancomycin alone or in combination with rifampin. Am J Med 82 suppl 4A:73–75Google Scholar
  17. Lewin CS (1987) Interactions of 4-quinolone antibacterials and antibiotics with Gram negative and Gram positive bacteria. PhD thesis, University of LondonGoogle Scholar
  18. Lewin CS, Smith JT (1988) Bactericidal mechanisms of ofloxacin. J Antimicrob Chemother 22 suppl C:1–8Google Scholar
  19. Lewin CS, Smith JT (1989) Interactions of the 4-quinolones with other antibacterials. J Med Microbiol 29:221–227PubMedCrossRefGoogle Scholar
  20. Matsunaga K, Yamaki H, Nishimuro T, Tanaka N (1986) Inhibition of DNA replication initiation by aminoglycoside antibiotics. Antimicrob Agents Chemother 30:468–474PubMedGoogle Scholar
  21. Neu HC, Labthavikul P (1982) In vitro activity of norfloxacin, a quinolone carboxylic acid, compared with that of ß-lactams, aminoglycosides and trimethoprim. Antimicrob Agents Chemother 22:23–27PubMedGoogle Scholar
  22. Neu HC, Chin N-X, Labthavikul P (1984) Antibacterial activity of coumermycin alone and in combination with other antibiotics. Antimicrob Agents Chemother 25:687–689PubMedGoogle Scholar
  23. Neu HC (1989) Synergy of fluoroquinolones with other antimicrobial agents. Rev Infect Dis 11 suppl 5:S1025–1035PubMedCrossRefGoogle Scholar
  24. Perronne CM, Malinverni R, Glauser MP (1987) Treatment of Staphylococcus aureus endocarditis in rats with coumermycin Al and ciprofloxacin, alone or in combination. Antimicrob Agents Chemother 31:539–543PubMedGoogle Scholar
  25. Ratcliffe NT, Smith JT (1983) Effects of magnesium on the activity of 4-quinolone antibacterial agents. J Pharm Pharmacol 35:61pGoogle Scholar
  26. Ratcliffe NT, Smith JT (1985) Ciprofloxacin’s bactericidal and inhibitory activity in urine. Chemiotherapia 4 suppl 2:385–386Google Scholar
  27. Scully BE, Parry MF, Neu HC (1986) Oral ciprofloxacin therapy for infections due to Pseudomonas aeruginosa. Lancet 11:819–822CrossRefGoogle Scholar
  28. Smith GM, Leyland MJ, Farrell I, Geddes AM (1988) A clinical microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients. J Antimicrob Chemother 1:647–655CrossRefGoogle Scholar
  29. Smith JT (1984) Awakening the slumbering potential of the 4-quinolone antibiotics. Pharm J 233:299–305Google Scholar
  30. Smith JT, Lewin CS (1988) Chemistry and mechanisms of action of the quinolone antibacterials. In: Andriole VT (ed) The quinolones, Academic Press, London, pp 23–82Google Scholar
  31. Smith SM, Eng RHK, Berman E (1986) The effect of ciprofloxacin on methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 17: 287–295PubMedCrossRefGoogle Scholar
  32. Tai PC, Davis BD (1985) The actions of antibiotics on the ribosome. In: Greenwood D, O’Grady F (eds) The scientific basis of antimicrobial Chemotherapy, Cambridge University Press, Cambridge, pp 45–69Google Scholar
  33. Tanaka N (1982) Mechanism of action of the aminoglycoside antibiotics. In: Umezawa H, Hooper IR (eds) Aminoglycoside antibiotics, Springer-Verlag, Berlin, Heidelberg, New York, pp 221–226Google Scholar
  34. Tanaka N, Matsunaga K, Yamaki H, Nishimura TK (1984) Inhibition of initiation of DNA synthesis by aminoglycoside antibiotics. Biochem Biophys Res Comms 122:460–465CrossRefGoogle Scholar
  35. Van der Auwera P (1985) Interaction of gentamicin, dibekacin, netilmicin and amikacin with various penicillins, cephalosporins, minocycline and new fluoroquinolones against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 16:581–587PubMedCrossRefGoogle Scholar
  36. Van der Auwera P, Jolly P (1985) Comparative in vitro activities of teicoplanin, vancomycin, coumermycin and ciprofloxacin alone and in combination with rifampicin or LM427 against Staphylococcus aureus. Abstracts of the 25th ICAAC:1058Google Scholar
  37. Wolfson JS, Hooper DC(1985) The fluoroquinolones: Structures, mechanisms of action and resistance and spectra of activity in vitro. Antimicrob Agents Chemother 28:581–586PubMedGoogle Scholar

References added in proof

  1. Kelsey SM, Wood ME, Shaw E, Jenkins GC, Newland AC (1990) A comparative study of intravenous ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin for the empirical treatment of fever in neutropenic patients. J Antimicrob Chemother 25, 149–157PubMedCrossRefGoogle Scholar
  2. Chan CC, Oppenheim BA, Anderson H, Swindell R, Scarffe JH (1989) Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric therapy in neutropenic patients. Antimicrob Agents Chemother 33: 87–91PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1990

Authors and Affiliations

  • C. S. Lewin
  • J. T. Smith

There are no affiliations available

Personalised recommendations